Differential membrane interactions of calcium channel blockers implications for antioxidant activity

Biochemical Pharmacology

Volumn 51, Issue 5, 1996, Pages 653-660

  Mason, R Preston ^a   Trumbore, Mark W ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antioxidants; Calcium channel blockers; Liposomes; X ray diffraction

Indexed keywords

ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; LIPOSOME; NIFEDIPINE; NISOLDIPINE;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ENTHALPY; HEART; LIPID BILAYER; LIPID PEROXIDATION; MEMBRANE STRUCTURE; PHASE TRANSITION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 0029965979     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(95)02238-4     Document Type: Article

References (28)

1. Ross R, The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809, 1986.
2. Steinberg D, Antioxidants and atherosclerosis: A current assessment. Circulation 84: 1420-1425, 1991.
3. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Nikutta P and Deckers JW, Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: Results of the INTACT study (International Trial on Antiatherosclerotic Therapy). Cardiovasc Drugs Ther 4: S1047-S1068, 1990.
4. Carew TE, Schwenke DC, and Steinberg DA, Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect. Proc Natl Acad Sci USA 84: 7725-7729, 1987.
5. Keogh AM and Schroeder JS, A review of calcium antagonists and atherosclerosis. J Cardiovasc Pharmacol 16: S28-S35, 1990.
6. Henry PD, Antiperoxidative actions of calcium antagonists and atherogenesis. J Cardiovasc Pharmacol 18: S6-S10, 1991.
7. Janis RA, Silver PJ and Triggle DJ, Drug action and calcium regulation. Adv Drug Res 16: 309-591, 1987.
8. Janero DR and Burghardt B, Antiperoxidant effects of dihydropyridine calcium antagonists. Biochem Pharmacol 38: 4344-4348, 1989.
9. Mak IT and Weglicki WB, Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation. Circ Res 66: 1449-1452, 1990.
10. Mak IT, Kramer JH and Weglicki WB, Antioxidant properties of active and inactive isomers of nicardipine in cardiac membranes, endothelial cells, and perfused rat hearts. Coron Artery Dis 3: 1095-1103, 1992.
11. Ondrias K, Misik V, Gergel D and Stasko A, Lipid peroxidation of phosphatidylcholine liposomes depressed by the calcium channel blockers nifedipine and verapamil and by the antiarrhythmicantihypoxic drug stobadine. Biochim Biophys Acta 1003: 238-245, 1989.
12. Janero DR, Burghardt B, and Lopez R, Protection of cardiac membrane phospholipid against oxidative injury by calcium antagonists. Biochem Pharmacol 37: 4197-4203, 1988.
13. Irita K, Fujita I, Takeshige K, Minakami S, and Yoshitake J, Calcium channel antagonist induced inhibition of superoxide production in human neutrophils. Mechanisms independent of antagonizing calcium influx. Biochem Pharmocol 35: 3465-3471, 1986.
14. Engineer FN and Sridhar R, Inhibition of rat heart and liver microsomal lipid peroxidation by nifedipine. Biochem Pharmacol 38: 1279-1285, 1989.
15. Bruegnot C, Maziere C, Auclair M, Mora L, Ronveaux MF, Salmon S, Santus R, Morliere P, Lenaers A, and Maziere JC, Calcium antagonists prevent monocyte and endothelial cell-induced modification of low density lipoproteins. Free Radic Res Commun 15: 91-100, 1991.
16. Li Q, Tallant A, and Cathcart MK, Dual calcium requirement for optimal lipid peroxidation of low density lipoprotein by activated human monocytes. J Clin Invest 91: 1499-1506, 1993.
17. Negre-Salvayre A and Salvayre R, Protection by calcium channel blockers (nifedipine, diltiazem and verapamil) against the toxicity of oxidized low density lipoprotein to cultured lymphoid cells. Br J Pharmacol 107: 738-744, 1992.
18. Watts JA and Kauder WF, Protection of isolated rat hearts by optical isomers of nisoldipine against hydrogen peroxide-induced injury is independent of calcium channel effects. FASEB J 9: A590, 1995.
19. Herbette LG, Chester DW, and Rhodes DG, Structural analysis of drug molecules in biological membranes. Biophys J 49: 91-94, 1986.
20. 2+ channel blockers to the membrane lipid bilayer. Mol Pharmacol 41: 315-321, 1992.
21. 2+-induced lipid peroxidation. Arch Biochem Biophys 206: 173-180, 1981.
22. Bangham AD, Standish MM and Watkins JC, Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238-252, 1965.
23. Herbette L, DeFoor P, Fleischer S, Pascolini D, Scarpa A and Blasie JK, The separate profile structures of the functional calcium pump protein and the phospholipid bilayer within isolated sarcoplasmic reticulum membranes determined by X-ray and neutron diffraction. Biochim Biophys Acta 817: 103-122, 1985.
24. Mason RP, Gonye GE, Chester DW and Herbette LG, Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes. Biophys J 55: 769-778, 1989.
25. Moody MF, X-ray diffraction pattern of nerve myelin: A method for determining the phases. Science 142: 1173-1174, 1963.
26. Herbette LG, MacAlister T, Ashavaid TF and Colvin RA, Structure-function studies of canine cardiac sarcolemmal membranes. II. Structural organization of the sarcolemmal membrane as determined by electron microscopy and lamellar X-ray diffraction. Biochim Biophys Acta 812: 609-623, 1985.
27. Young HS, Skita V, Mason RP and Herbette LG, Molecular basis for the inhibition of 1,4-dihydropyridine calcium channel drugs to their receptors by a nonspecific site interaction mechanism. Biophys J 61: 1244-1255, 1992.
28. Jain MK and Wu NM, Effect of small molecules on the dipalmitoyl lecithin liposomal bilayer. J Membr Biol 34: 157-201, 1977.